Radiation and Hormone Therapy Combo May Help Prevent Cancer’s Return After Prostatectomy

Radiation and Hormone Therapy Combo May Help Prevent Cancer’s Return After Prostatectomy
Prostate cancer patients who show signs of disease progression after surgery to remove the prostate may benefit by combining standard therapy with short-term androgen deprivation (STAD) and pelvic lymph node radiation therapy (PLNRT), a clinical trial reports. The research, "Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiation Therapy: The NRG Oncology/RTOG 0534 SPPORT Trial," was recently presented at the American Society for Radiation Oncology (ASTRO) 2018 Annual Meeting, held in San Antonio, Texas. Patients who undergo prostate removal — called prostatectomy — often show signs of cancer's return in the form of an increase in blood prostate-specific antigen (PSA) levels. The current standard therapy is prostate bed radiation therapy (PBRT), but even then, 30% to 40% of patients see their PSA levels increase again within 5 to 10 years. Radiation therapy directed at the prostate lymph nodes and androgen deprivation therapy are thought to be effective complementary therapies, but scientific evidence was lacking without a clinical trial. The SPPORT Phase 3 trial (NCT00567580) was thus designed to test the benefits of adding STAD, or STAD plus PLNRT, to PBRT in patients with rising levels of PSA after prostatectomy. This is the f
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *